The new microdose capsules are produced entirely in-house at Optimi’s GMP-certified facility in Princeton, British Columbia. The process involves cultivating the mushrooms, extracting the active pharmaceutical ingredient, and handling final encapsulation under a Health Canada Drug Establishment License. These products are now available to authorized clinical research organizations globally.

CEO Dane Stevens noted that while researchers often prefer natural sources, the inconsistent psilocybin content in dried mushrooms creates significant hurdles for clinical validation. These standardized doses provide a reliable alternative for regimens like the Fadiman or Stamets protocols, which require precision to mitigate tolerance buildup. This expansion complements the company’s existing 5mg capsule, which is already utilized for treatment-resistant depression under Australia’s Authorized Prescriber Scheme.